Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Clinical pharmacogenetics receptors

Burris HA, 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW5720I6), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. JCfiri Oncol2005 23 5305-5313. Zaks T, Akkari A, Briley L et al. Role of pharmacogenetic studies in early clinical development Phase I studies with lapatinib. JCfiW Oncol 2006 24 3029. [Pg.323]

Kok-Yuen H, Tong JG (2005) Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytrytamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 19 606-611. [Pg.223]

Blum K, Sheridan PJ, Wood RC, et al Dopamine D2 receptor gene variants association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5(3) 121-141,1995 Bolt HM Interactions between clinically used drugs and oral contraceptives. Environ Health Perspect 102 (suppl 9) 35-38,1994 Branch RA, Salih SY, Homeida M Racial differences in drug metabolizing ability a study with antipyrine in the Sudan. Clin Pharmacol Ther 24 283-286,1978... [Pg.28]

See other pages where Clinical pharmacogenetics receptors is mentioned: [Pg.251]    [Pg.12]    [Pg.170]    [Pg.4]    [Pg.4]    [Pg.29]    [Pg.372]    [Pg.215]    [Pg.116]    [Pg.139]    [Pg.140]    [Pg.143]    [Pg.152]    [Pg.272]    [Pg.365]    [Pg.430]    [Pg.207]    [Pg.208]    [Pg.535]    [Pg.55]    [Pg.47]    [Pg.256]    [Pg.265]    [Pg.342]    [Pg.65]    [Pg.281]    [Pg.180]    [Pg.29]    [Pg.46]    [Pg.189]    [Pg.190]    [Pg.192]    [Pg.205]    [Pg.206]    [Pg.208]    [Pg.223]    [Pg.245]    [Pg.250]    [Pg.511]    [Pg.615]    [Pg.652]    [Pg.6]    [Pg.116]    [Pg.122]    [Pg.150]   


SEARCH



Clinical pharmacogenetics

Pharmacogenetic

Pharmacogenetics

© 2024 chempedia.info